Literature DB >> 28628228

Epigenetic mechanisms underlying NMDA receptor hypofunction in the prefrontal cortex of juvenile animals in the MAM model for schizophrenia.

Yelena Gulchina1, Song-Jun Xu2, Melissa A Snyder1, Felice Elefant2, Wen-Jun Gao1.   

Abstract

Schizophrenia (SCZ) is characterized not only by psychosis, but also by working memory and executive functioning deficiencies, processes that rely on the prefrontal cortex (PFC). Because these cognitive impairments emerge prior to psychosis onset, we investigated synaptic function during development in the neurodevelopmental methylazoxymethanol (MAM) model for SCZ. Specifically, we hypothesize that N-methyl-D-aspartate receptor (NMDAR) hypofunction is attributable to reductions in the NR2B subunit through aberrant epigenetic regulation of gene expression, resulting in deficient synaptic physiology and PFC-dependent cognitive dysfunction, a hallmark of SCZ. Using western blot and whole-cell patch-clamp electrophysiology, we found that the levels of synaptic NR2B protein are significantly decreased in juvenile MAM animals, and the function of NMDARs is substantially compromised. Both NMDA-mEPSCs and synaptic NMDA-eEPSCs are significantly reduced in prelimbic PFC (plPFC). This protein loss during the juvenile period is correlated with an aberrant increase in enrichment of the epigenetic transcriptional repressor RE1-silencing transcription factor (REST) and the repressive histone marker H3K27me3 at the Grin2b promoter, as assayed by ChIP-quantitative polymerase chain reaction. Glutamate hypofunction has been a prominent hypothesis in the understanding of SCZ pathology; however, little attention has been given to the NMDAR system in the developing PFC in models for SCZ. Our work is the first to confirm that NMDAR hypofunction is a feature of early postnatal development, with epigenetic hyper-repression of the Grin2b promoter being a contributing factor. The selective loss of NR2B protein and subsequent synaptic dysfunction weakens plPFC function during development and may underlie early cognitive impairments in SCZ models and patients. Read the Editorial Highlight for this article on page 264.
© 2017 International Society for Neurochemistry.

Entities:  

Keywords:  ChIP; NMDA receptors; animal model; histone modification H3K27me3; juvenile; repressor protein REST/NRSF; schizophrenia

Mesh:

Substances:

Year:  2017        PMID: 28628228      PMCID: PMC5653427          DOI: 10.1111/jnc.14101

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  65 in total

1.  Expression of the NR2B-NMDA receptor trafficking complex in prefrontal cortex from a group of elderly patients with schizophrenia.

Authors:  L V Kristiansen; B Bakir; V Haroutunian; J H Meador-Woodruff
Journal:  Schizophr Res       Date:  2010-03-29       Impact factor: 4.939

Review 2.  Cellular basis of working memory.

Authors:  P S Goldman-Rakic
Journal:  Neuron       Date:  1995-03       Impact factor: 17.173

Review 3.  NR2B subunit in the prefrontal cortex: A double-edged sword for working memory function and psychiatric disorders.

Authors:  Sarah A Monaco; Yelena Gulchina; Wen-Jun Gao
Journal:  Neurosci Biobehav Rev       Date:  2015-07-02       Impact factor: 8.989

4.  Neuropsychological evidence for frontostriatal dysfunction in schizophrenia.

Authors:  R Elliott; P J McKenna; T W Robbins; B J Sahakian
Journal:  Psychol Med       Date:  1995-05       Impact factor: 7.723

Review 5.  Glutamatergic transmission in schizophrenia: from basic research to clinical practice.

Authors:  Joshua Kantrowitz; Daniel C Javitt
Journal:  Curr Opin Psychiatry       Date:  2012-03       Impact factor: 4.741

Review 6.  To model a psychiatric disorder in animals: schizophrenia as a reality test.

Authors:  B K Lipska; D R Weinberger
Journal:  Neuropsychopharmacology       Date:  2000-09       Impact factor: 7.853

7.  Neonatal lesions of the ventral hippocampus in rats lead to prefrontal cognitive deficits at two maturational stages.

Authors:  J-P Marquis; S Goulet; F Y Doré
Journal:  Neuroscience       Date:  2006-03-31       Impact factor: 3.590

8.  NMDA hypofunction as a convergence point for progression and symptoms of schizophrenia.

Authors:  Melissa A Snyder; Wen-Jun Gao
Journal:  Front Cell Neurosci       Date:  2013-03-27       Impact factor: 5.505

9.  Network-assisted investigation of combined causal signals from genome-wide association studies in schizophrenia.

Authors:  Peilin Jia; Lily Wang; Ayman H Fanous; Carlos N Pato; Todd L Edwards; Zhongming Zhao
Journal:  PLoS Comput Biol       Date:  2012-07-05       Impact factor: 4.475

10.  Cognitive deficits and functional outcome in schizophrenia.

Authors:  Christopher R Bowie; Philip D Harvey
Journal:  Neuropsychiatr Dis Treat       Date:  2006-12       Impact factor: 2.570

View more
  19 in total

1.  Juvenile treatment with mGluR2/3 agonist prevents schizophrenia-like phenotypes in adult by acting through GSK3β.

Authors:  Bo Xing; Genie Han; Min-Juan Wang; Melissa A Snyder; Wen-Jun Gao
Journal:  Neuropharmacology       Date:  2018-05-14       Impact factor: 5.250

2.  Elevated glutamate, glutamine and GABA levels and reduced taurine level in a schizophrenia model using an in vitro proton nuclear magnetic resonance method.

Authors:  Jingyu Yang; Huiling Guo; Dandan Sun; Jia Duan; Xiaoping Rao; Fuqiang Xu; Anne Manyande; Yanqing Tang; Jie Wang; Fei Wang
Journal:  Am J Transl Res       Date:  2019-09-15       Impact factor: 4.060

3.  The methylazoxymethanol acetate rat model: molecular and epigenetic effect in the developing prefrontal cortex: An Editorial Highlight for 'Epigenetic mechanisms underlying NMDA receptor hypofunction in the prefrontal cortex of juvenile animals in the MAM model for schizophrenia' on page 320.

Authors:  Xiyu Zhu; Felipe V Gomes; Anthony A Grace
Journal:  J Neurochem       Date:  2017-09-05       Impact factor: 5.372

Review 4.  Dopaminergic dysfunction and excitatory/inhibitory imbalance in treatment-resistant schizophrenia and novel neuromodulatory treatment.

Authors:  Masataka Wada; Yoshihiro Noda; Yusuke Iwata; Sakiko Tsugawa; Kazunari Yoshida; Hideaki Tani; Yoji Hirano; Shinsuke Koike; Daiki Sasabayashi; Haruyuki Katayama; Eric Plitman; Kazutaka Ohi; Fumihiko Ueno; Fernando Caravaggio; Teruki Koizumi; Philip Gerretsen; Takefumi Suzuki; Hiroyuki Uchida; Daniel J Müller; Masaru Mimura; Gary Remington; Anthony A Grace; Ariel Graff-Guerrero; Shinichiro Nakajima
Journal:  Mol Psychiatry       Date:  2022-04-20       Impact factor: 15.992

Review 5.  The use of antioxidant compounds in the treatment of first psychotic episode: Highlights from preclinical studies.

Authors:  Stefania Schiavone; Luigia Trabace
Journal:  CNS Neurosci Ther       Date:  2018-03-14       Impact factor: 5.243

6.  The histone demethylase KDM6B in the medial prefrontal cortex epigenetically regulates cocaine reward memory.

Authors:  Yu-Xiang Zhang; Rita C Akumuo; Rodrigo A España; Chun-Xia Yan; Wen-Jun Gao; Yan-Chun Li
Journal:  Neuropharmacology       Date:  2018-08-27       Impact factor: 5.250

Review 7.  The origin of NMDA receptor hypofunction in schizophrenia.

Authors:  Kazu Nakazawa; Kiran Sapkota
Journal:  Pharmacol Ther       Date:  2019-10-16       Impact factor: 12.310

Review 8.  NMDA receptor hypofunction for schizophrenia revisited: Perspectives from epigenetic mechanisms.

Authors:  Melissa A Snyder; Wen-Jun Gao
Journal:  Schizophr Res       Date:  2019-04-09       Impact factor: 4.939

9.  SK Channel Modulates Synaptic Plasticity by Tuning CaMKIIα/β Dynamics.

Authors:  Amita Shrestha; Razia Sultana; Charles C Lee; Olalekan M Ogundele
Journal:  Front Synaptic Neurosci       Date:  2019-10-31

10.  GLYX-13 Ameliorates Schizophrenia-Like Phenotype Induced by MK-801 in Mice: Role of Hippocampal NR2B and DISC1.

Authors:  Dongsheng Zhou; Dan Lv; Zhen Wang; Yanhua Zhang; Zhongming Chen; Chuang Wang
Journal:  Front Mol Neurosci       Date:  2018-04-11       Impact factor: 5.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.